Preoperative Decolonization and Surgical Site Infections in Orthopaedic Surgery - 2 Year Outcome in Prosthetic Surgery (DECO-SSI)
Primary Purpose
Staphylococcus Aureus, Orthopaedic Surgery, Surgical Site Infection
Status
Completed
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun
BACTROBAN® Nasal ong
Sponsored by
About this trial
This is an interventional prevention trial for Staphylococcus Aureus
Eligibility Criteria
Inclusion Criteria:
- older than 16 years
- planned elective orthopedic procedure
- Decolonization protocol can be performed timely
Exclusion Criteria:
- No orthopedic prosthetic surgery planned
- Allergy to mupirocin or chlorhexidine
- Presence of a nasal foreign body
- No informed consent
- undergoing treatment/surgery for a documented infection
- already participating in the study
Sites / Locations
- Sonnenhofspital, Lindenhofgruppe
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
No Intervention
Experimental
No Intervention
Arm Label
Carrier group - intervention
Carrier group - control
Non - carrier group - intervention
Non - carrier group - control
Arm Description
BACTROBAN® Nasal ong, 3g, GSK Lifo-Scrub sol 4%®, 500ml, B. Braun
Lifo-Scrub sol 4%®, 500ml, B. Braun
Outcomes
Primary Outcome Measures
Surgical site infections
according CDC-Criteria
Secondary Outcome Measures
Overall mortality
Death related to infection
Documented bacteria
of PJI
Time to PJI and death
counting from operation date
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03962907
Brief Title
Preoperative Decolonization and Surgical Site Infections in Orthopaedic Surgery - 2 Year Outcome in Prosthetic Surgery
Acronym
DECO-SSI
Official Title
Preoperative Decolonization and Surgical Site Infections in Orthopaedic Surgery: a Prospective Randomized Controlled Trial - 2 Year Outcome in Prosthetic Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
January 1, 2019 (Actual)
Primary Completion Date
March 30, 2020 (Actual)
Study Completion Date
June 30, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lindenhofgruppe AG
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Surgical site infections in orthopaedic surgery are a major problem. Decolonization has been suggested to reduce infection rates. The study was designed as a prospective, controlled, randomized, single-blinded trial to assess the influence of a decolonization procedure in S. aureus and non - S. aureus carriers. In this trial the 2 - year outcome in the subpopulation of prosthetic elective orthopaedic surgery will be evaluated.
Detailed Description
To verify the main hypothesis, a prospective controlled randomized interventional trial with 2 parallel groups of patients of the Sonnenhof hospital undergoing an elective knee- or hip implant surgery was designed. A superiority framework for the decolonization procedure was used. All patients planned for such a procedure will be recruited during preoperative consultation by the orthopedic surgeons or by post and phone. Written informed consent will be obtained at this occasion. Study participants were screened 2-4 weeks prior intervention for nasal S. aureus colonization.
Study participants were allocated on a 1:1 basis either to an intervention or to a control group, but prosthesis implantation was not defined as randomization criteria in the initial trial. Randomization was stratified for important risk factors of SSI; procedure type (upper extremities and pelvic/hip, spine, knee and foot) and ASA-criteria (I, II, III -V). Stratification-groups were chosen in function of SSI's rate and expected number of operations/year. Randomization list were generated by the CTU and allocation was concealed using central randomization that was implemented in the REDCap data entry system.
One week prior to hospitalization patients in the intervention group received a decolonization kit by mail with instructions to apply mupirocin ointment 2% (BACTROBAN Nasal ong 3g, GSK) in each nostril 30mg (which corresponds approximately the same amount as the volume of a pea) twice a day and to shower daily (starting with the face, then from top to bottom the whole body emphasizing especially on nose, axillaries and pelvic region and then rinse. In a second time starting with the hair and then repeat the whole body. Dry with a proper towel (one for the 5 days)) with 25ml chlorhexidine gluconate soap, (Lifo-Scrub sol 4 % 500ml, B. Braun) during 5 days prior surgery. For non S. aureus carriers only skin cleansing without intranasal mupirocin application was used. This dosing schedule, mode of administration and treatment periods correspond to the allowed and recommended standards of Swissmedic and were not modified in this trial. Decolonization occured before hospitalization, as a fully completed course before surgery has been more effective. In some of the previous trials decolonization took place only at the beginning of hospitalization. The decolonization procedure was only completed after surgery had taken place and this possibly affected the results.
For practical reasons the use of a placebo kit within the control group abandoned. Operators, who are also the outcome assessors, will be blinded for either the carrier status or the decolonization procedure. Study participants will be told not to inform surgeons about performed decolonization procedure.
The incidence of PJI at two years in the intervention and control group will be assessed by phone interview.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Staphylococcus Aureus, Orthopaedic Surgery, Surgical Site Infection, Prevention
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
two groups: S. aureus carrier and non-carriers. Both groups have an intervention and control arm
Masking
ParticipantOutcomes Assessor
Masking Description
Participants are not told colonization status or study arm. Outcome Assessor are not informed as well on this informations.
Allocation
Randomized
Enrollment
1318 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Carrier group - intervention
Arm Type
Experimental
Arm Description
BACTROBAN® Nasal ong, 3g, GSK Lifo-Scrub sol 4%®, 500ml, B. Braun
Arm Title
Carrier group - control
Arm Type
No Intervention
Arm Title
Non - carrier group - intervention
Arm Type
Experimental
Arm Description
Lifo-Scrub sol 4%®, 500ml, B. Braun
Arm Title
Non - carrier group - control
Arm Type
No Intervention
Intervention Type
Drug
Intervention Name(s)
Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun
Intervention Description
5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.
Intervention Type
Drug
Intervention Name(s)
BACTROBAN® Nasal ong
Intervention Description
Mupirocin, BACTROBAN® Nasal ong, 3g, GSK
Primary Outcome Measure Information:
Title
Surgical site infections
Description
according CDC-Criteria
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Overall mortality
Time Frame
2 years
Title
Death related to infection
Time Frame
2 years
Title
Documented bacteria
Description
of PJI
Time Frame
2 years
Title
Time to PJI and death
Description
counting from operation date
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
older than 16 years
planned elective orthopedic procedure
Decolonization protocol can be performed timely
Exclusion Criteria:
No orthopedic prosthetic surgery planned
Allergy to mupirocin or chlorhexidine
Presence of a nasal foreign body
No informed consent
undergoing treatment/surgery for a documented infection
already participating in the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jan Brügger, MD
Organizational Affiliation
Lindenhofgruppe
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sonnenhofspital, Lindenhofgruppe
City
Bern
ZIP/Postal Code
3006
Country
Switzerland
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Preoperative Decolonization and Surgical Site Infections in Orthopaedic Surgery - 2 Year Outcome in Prosthetic Surgery
We'll reach out to this number within 24 hrs